A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs DCVAC OvCa (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms VITALIA
- Sponsors SOTIO
- 31 Oct 2019 Planned End Date changed from 1 Dec 2026 to 1 Mar 2027.
- 31 Oct 2019 Planned primary completion date changed from 1 Oct 2026 to 1 Mar 2027.
- 31 Oct 2019 Planned initiation date changed from 1 Sep 2019 to 1 May 2020.